Impact of Fixed Combination of Metformin and Pioglitazone on Insulin Resistance of Patients with Type 2 Diabetes: Results of a Randomized Open-Label Study

References

• Tinajero MG, Malik VS. An update on the epidemiology of type 2 diabetes: a global perspective. Endocrinol Metab Clin North Am. 2021;50(3):337–355. doi:10.1016/j.ecl.2021.05.013
   PubMed Web of Science ®Google Scholar
• Pearson ER. Type 2 diabetes: a multifaceted disease. Diabetologia. 2019;62(7):1107–1112. doi:10.1007/s00125-019-4909-y
   PubMed Web of Science ®Google Scholar
• Yaribeygi H, Farrokhi FR, Butler AE, et al. Insulin resistance: review of the underlying molecular mechanisms. J Cell Physiol. 2019;234(6):8152–8161. doi:10.1002/jcp.27603
   PubMed Web of Science ®Google Scholar
• Ndisang JF, Vannacci A, Rastogi S. Insulin resistance, type 1 and type 2 diabetes, and related complications 2017. J Diabetes Res. 2017;2017:1478294. doi:10.1155/2017/1478294
   PubMed Web of Science ®Google Scholar
• Kostov K. Effects of magnesium deficiency on mechanisms of insulin resistance in type 2 diabetes: focusing on the processes of insulin secretion and signaling. Int J Mol Sci. 2019;20(6):1351. doi:10.3390/ijms20061351
   PubMed Web of Science ®Google Scholar
• Laakso M. Biomarkers for type 2 diabetes. Mol Metab. 2019;27(Suppl 2):S139–s146. doi:10.1016/j.molmet.2019.06.016
   Google Scholar
• Tanase DM, Gosav EM, Costea CF, et al. The intricate relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). J Diabetes Res. 2020;2020:3920196. doi:10.1155/2020/3920196
   PubMed Web of Science ®Google Scholar
• Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol. 2021;9(8):525–544. doi:10.1016/S2213-8587(21)00113-3
   PubMed Web of Science ®Google Scholar
• Mastrototaro L, Roden M. Insulin resistance and insulin sensitizing agents. Metabolism. 2021;125:154892. doi:10.1016/j.metabol.2021.154892
   PubMed Web of Science ®Google Scholar
• Eguchi K, Tomizawa H, Ishikawa J, et al. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Hypertens Res. 2007;30(1):23–30. doi:10.1291/hypres.30.23
   PubMed Web of Science ®Google Scholar
• Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia. 2006;49(3):434–441. doi:10.1007/s00125-006-0141-7
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Viscoli CM, Young LH, et al. Pioglitazone prevents diabetes in patients with insulin resistance and cerebrovascular disease. Diabetes Care. 2016;39(10):1684–1692. doi:10.2337/dc16-0798
   PubMed Web of Science ®Google Scholar
• Perez A, Zhao Z, Jacks R, et al. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Curr Med Res Opin. 2009;25(12):2915–2923. doi:10.1185/03007990903350011
   PubMed Web of Science ®Google Scholar
• Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1730–1735. doi:10.2337/dc15-0355
   PubMed Web of Science ®Google Scholar
• Ruud J, Steculorum SM, Brüning JC. Neuronal control of peripheral insulin sensitivity and glucose metabolism. Nat Commun. 2017;8(1):15259. doi:10.1038/ncomms15259
   PubMed Web of Science ®Google Scholar
• Kullmann S, Hummel J, Wagner R, et al. empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: a randomized, double-blind, placebo-controlled, Phase 2 trial. Diabetes Care. 2022;45(2):398–406. doi:10.2337/dc21-1136
   PubMed Web of Science ®Google Scholar
• Nunez Lopez YO, Retnakaran R, Zinman B, et al. Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes. Mol Metab. 2019;20:63–78. doi:10.1016/j.molmet.2018.11.003
   PubMed Web of Science ®Google Scholar
• Baldi S, Bonnet F, Laville M, et al. Influence of apolipoproteins on the association between lipids and insulin sensitivity: a cross-sectional analysis of the RISC study. Diabetes Care. 2013;36(12):4125–4131. doi:10.2337/dc13-0682
   PubMed Web of Science ®Google Scholar
• Yang L, Liang H, Liu X, et al. Islet function and insulin sensitivity in latent autoimmune diabetes in adults taking sitagliptin: a randomized trial. J Clin Endocrinol Metab. 2021;106(4):e1529–e1541. doi:10.1210/clinem/dgab026
   PubMed Web of Science ®Google Scholar
• Luukkonen PK, Zhou Y, Sädevirta S, et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J Hepatol. 2016;64(5):1167–1175. doi:10.1016/j.jhep.2016.01.002
   PubMed Web of Science ®Google Scholar
• Lee SH, Park SY, Choi CS. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J. 2022;46(1):15–37. doi:10.4093/dmj.2021.0280
   PubMed Web of Science ®Google Scholar
• Shigiyama F, Kumashiro N, Miyagi M, et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol. 2017;16(1):84. doi:10.1186/s12933-017-0564-0
   PubMedGoogle Scholar
• Hanefeld M, Pfützner A, Forst T, et al. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study. Cardiovasc Diabetol. 2011;10:65. doi:10.1186/1475-2840-10-65
   PubMed Web of Science ®Google Scholar
• Kaku K. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial. Curr Med Res Opin. 2009;25(5):1111–1119. doi:10.1185/03007990902820816
   PubMed Web of Science ®Google Scholar
• Elkind-Hirsch KE, Seidemann E, Harris R. A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus. Am J Obstet Gynecol MFM. 2020;2(3):100139. doi:10.1016/j.ajogmf.2020.100139
   PubMed Web of Science ®Google Scholar
• Wang Y, Hu X, Liu X, et al. An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients. Ther Clin Risk Manag. 2016;12:1113–1131. doi:10.2147/TCRM.S112236
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 Inhibitors. Circ Res. 2018;122(10):1439–1459. doi:10.1161/CIRCRESAHA.117.311588
   PubMed Web of Science ®Google Scholar
• Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752–772. doi:10.1161/CIRCULATIONAHA.116.021887
   PubMed Web of Science ®Google Scholar
• El-Sayed N, Mostafa YM, AboGresha NM, et al. Dapagliflozin attenuates diabetic cardiomyopathy through erythropoietin up-regulation of AKT/JAK/MAPK pathways in streptozotocin-induced diabetic rats. Chem Biol Interact. 2021;347:109617. doi:10.1016/j.cbi.2021.109617
   PubMed Web of Science ®Google Scholar
• Joannides CN, Mangiafico SP, Waters MF, et al. Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity. Diabetes Obes Metab. 2017;19(8):1135–1146. doi:10.1111/dom.12923
   PubMed Web of Science ®Google Scholar
• Tsai KF, Chen Y-L, Chiou TT-Y, et al. Emergence of SGLT2 inhibitors as powerful antioxidants in human diseases. Antioxidants. 2021;10(8):1166. doi:10.3390/antiox10081166
   Web of Science ®Google Scholar
• Zhang E, Zhao Y, Hu H. Impact of sodium glucose cotransporter 2 inhibitors on nonalcoholic fatty liver disease complicated by diabetes mellitus. Hepatol Commun. 2021;5(5):736–748. doi:10.1002/hep4.1611
   PubMed Web of Science ®Google Scholar
• Han T, Fan Y, Gao J, et al. Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice. Adipocyte. 2021;10(1):446–455. doi:10.1080/21623945.2021.1979277
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Inzucchi S, Abdul-Ghani M, et al. Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019;16(2):133–143. doi:10.1177/1479164118825376
   PubMed Web of Science ®Google Scholar
• Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314(3):265–277. doi:10.1001/jama.2015.7996
   PubMed Web of Science ®Google Scholar
• Einhorn D, Fonseca V. Revisiting the use of Pioglitazone in the treatment of type 2 diabetes. Endocr Pract. 2016;22(11):1343–1346. doi:10.4158/EP161409.CO
   PubMed Web of Science ®Google Scholar
• Ipsen E, Madsen KS, Chi Y, et al. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020;11(11):Cd013516. doi:10.1002/14651858.CD013516.pub2
   PubMedGoogle Scholar
• Della Pepa G, Russo M, Vitale M, et al. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. Diabetes Res Clin Pract. 2021;178:108984. doi:10.1016/j.diabres.2021.108984
   PubMed Web of Science ®Google Scholar
• Nesti L, Tricò D, Mengozzi A, et al. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovasc Diabetol. 2021;20(1):109. doi:10.1186/s12933-021-01294-7
   PubMed Web of Science ®Google Scholar
• Lee M, Saver JL, Liao H-W, et al. Pioglitazone for secondary stroke prevention: a systematic review and meta-analysis. Stroke. 2017;48(2):388–393. doi:10.1161/STROKEAHA.116.013977
   PubMed Web of Science ®Google Scholar
• Flory J, Lipska K. Metformin in 2019. JAMA. 2019;321(19):1926–1927. doi:10.1001/jama.2019.3805
   PubMed Web of Science ®Google Scholar
• Zhang K, Yang W, Dai H, et al. Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus: results from meta-analysis. Diabetes Res Clin Pract. 2020;160:108001. doi:10.1016/j.diabres.2020.108001
   PubMed Web of Science ®Google Scholar
• Han Y, Xie H, Liu Y, et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019;18(1):96. doi:10.1186/s12933-019-0900-7
   PubMedGoogle Scholar
• Li T, Providencia R, Mu N, et al. Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2021;20(1):30. doi:10.1186/s12933-020-01202-5
   PubMed Web of Science ®Google Scholar
• Bromage DI, Godec TR, Pujades-Rodriguez M, et al. Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study. Cardiovasc Diabetol. 2019;18(1):168. doi:10.1186/s12933-019-0972-4
   PubMed Web of Science ®Google Scholar
• Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017;60(9):1620–1629. doi:10.1007/s00125-017-4337-9
   PubMed Web of Science ®Google Scholar
• Lamanna C, Monami M, Marchionni N, et al. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221–228. doi:10.1111/j.1463-1326.2010.01349.x
   PubMed Web of Science ®Google Scholar
• Seufert J. A fixed-dose combination of pioglitazone and metformin: a promising alternative in metabolic control. Curr Med Res Opin. 2006;22(Suppl 2):S39–48. doi:10.1185/030079906X121002
   PubMedGoogle Scholar
• Šebeková K, Gurecká R, Csongová M, et al. Lean insulin-resistant young adults display increased cardiometabolic risk: a retrospective cross-sectional study. Diabetes Res Clin Pract. 2022;185:109217. doi:10.1016/j.diabres.2022.109217
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P. Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes. Diabetes Res Clin Pract. 2011;91(3):265–270. doi:10.1016/j.diabres.2010.08.001
   PubMed Web of Science ®Google Scholar
• Derosa G, Tinelli C, Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes Metab. 2009;11(12):1091–1099. doi:10.1111/j.1463-1326.2009.01087.x
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473–1478. doi:10.2337/dc11-1693
   PubMed Web of Science ®Google Scholar
• Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13(6):610–630. doi:10.2337/diacare.13.6.610
   PubMed Web of Science ®Google Scholar
• Luo W, Ai L, Wang B-F, et al. High glucose inhibits myogenesis and induces insulin resistance by down-regulating AKT signaling. Biomed Pharmacother. 2019;120:109498. doi:10.1016/j.biopha.2019.109498
   PubMed Web of Science ®Google Scholar